Aurinia Pharmaceuticals Inc. (NasdaqGM: AUPH)
Health Care · Biotechnology · CA
$16.75
+1.09% today · +38.0% 1Y
Aurinia Pharmaceuticals Inc. (NasdaqGM: AUPH) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.23B and employs 128 people.
Over the last twelve months the share price has gained 38.0%, trading between 10.34 and 19.25.
Tweenvest scores Aurinia Pharmaceuticals Inc. across four factors: quality 71/100, value 48/100, growth 100/100. Its strongest factor is growth.
AUPH price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.23B
- Revenue (TTM)
- $311.51M
- P/E
- 7.27
- EPS
- 2.30
- Dividend yield
- —
- Beta (5Y)
- 1.40
- 52-week high
- $19.25
- 52-week low
- $10.34
- Avg volume (3M)
- —
- Shares outstanding
- 133.05M
- Employees
- 128
- Next earnings
- —
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
- ISIN
- CA05156V1022
- Founded
- 1993
- Listed since
- Sep 3, 2014
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.